Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06748040 · ClinicalTrials.gov registry record · NA
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 1,874
- Enrollment target
NCT06748040 is a NA study that has completed, run by Duke University. The registered enrollment target is 1,874 participants.
The verdict
NCT06748040, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,874 participants
- Enrollment target
Study Summary
This is a substudy of GUARDD-US (Genetic testing to Understand and Address Renal Disease Disparities across the United States, NCT04191824). Its primary purpose is to determine the effect of knowledge of genetic test results that predict efficacy of various antihypertensive medications on change in SBP (systolic blood pressure) from baseline to 3 months in APOL1 (apolipoprotein L1) negative individuals at participating sites.
Interventions
- OTHER Timing of return of results
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,874 participants |
| Start Date | 2020-07-10 |
| Est. Completion | 2024-05-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06748040
The ClinicalTrials.gov registry entry for NCT06748040 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,874 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Timing of return of results is the first listed.
NCT06748040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06748040 about?
NCT06748040 is a clinical study titled "Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy". This is a substudy of GUARDD-US (Genetic testing to Understand and Address Renal Disease Disparities across the United States, NCT04191824). Its primary purpose is to determine the effect of knowledge of genetic test results that predict efficacy of various antihypertensive medications on change in ...
What is the current status of trial NCT06748040?
This trial is currently completed. It is a NA study. The enrollment target is 1,874 participants. The study started on 2020-07-10. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT06748040?
The interventions under investigation include: Timing of return of results (OTHER).
Who is sponsoring clinical trial NCT06748040?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.